On June 17, 2024, the board of directors of TRxADE Health, Inc. appointed Subbarao Jayanthi to the Board. It has not yet been determined on which committees of the Board Mr. Jayanthi will serve. Subbarao Jayanthi, is the Managing Partner of RxC International, LLC and has been with the company since May 2013.

RxC International is a strategy consulting firm advising biopharma companies on growth strategies and while at the firm Mr. Jayanthi has advised senior executives and board members at several biopharma companies on corporate strategy, portfolio strategy, and licensing/M&A transactions in the US, EU, and Japan. Mr. Jayanthi is also a Board Member and Chief Business Officer of Interlude Biopharma, a GI company with three late-stage novel medications under development for gastrointestinal disorders. He is also a Senior Advisor to Modig Life Sciences, a rare disease company developing an antisense oligonucleotide for a fatal neurodegenerative disease.

Before this, Subbarao was the head of business planning at Daiichi Sankyo, a Top 20 global biopharma company. He spent a decade in leadership positions at global strategy consulting firms such as BCG and others, earlier in his career. He has authored books on biopharma commercialization, value chain management, and investments.

He has an MBA in strategy, finance, and marketing from Kellogg School of Management at Northwestern University. Board believes that Mr. Jayanthi is well qualified to serve on the Board because of his experience advising biopharma companies. On June 17, 2024, Narasimhan Mani voluntarily resigned as a director of the Company.

His decision to resign was not the result of any dispute or disagreement with the Company or any matter relating to the Company?s operations, policies or practices.